Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

This study demonstrates the feasibility of conducting trials in mesothelioma patients who have failed first-line therapy

David M. Jackman

2008

Scholarcy highlights

Need more features? Save interactive summary cards to your Scholarcy Library.